Myovant Sciences Ltd (MYOV) Stock Price & Overview
NYSE:MYOV • BMG637AM1024
Current stock price
The current stock price of MYOV is 26.98 USD. Today MYOV is down by -0.04%. In the past month the price increased by 0.33%. In the past year, price increased by 125.4%.
MYOV Key Statistics
- Market Cap
- 2.623B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.91
- Dividend Yield
- N/A
MYOV Stock Performance
MYOV Stock Chart
MYOV Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MYOV. When comparing the yearly performance of all stocks, MYOV is one of the better performing stocks in the market, outperforming 98.07% of all stocks.
MYOV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYOV. MYOV has a bad profitability rating. Also its financial health evaluation is rather negative.
MYOV Earnings
MYOV Forecast & Estimates
10 analysts have analysed MYOV and the average price target is 27.54 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 26.98.
For the next year, analysts expect an EPS growth of 19.42% and a revenue growth 81.1% for MYOV
MYOV Groups
Sector & Classification
MYOV Financial Highlights
Over the last trailing twelve months MYOV reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS increased by 22.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MYOV Ownership
MYOV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 368.381B | ||
| AMGN | AMGEN INC | 15.48 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.88 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.71 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.33 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.62 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MYOV
Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. The firm is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company develops Relugolix for the treatment of men with advanced prostate cancer. The firm is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
Company Info
IPO: 2016-10-27
Myovant Sciences Ltd
Ste 1 3rd Fl, 11/12 St. James's Square
London SW1Y 4LB GB
CEO: David Marek
Employees: 579
Phone: 442074003351.0
Myovant Sciences Ltd / MYOV FAQ
What does MYOV do?
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. The firm is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company develops Relugolix for the treatment of men with advanced prostate cancer. The firm is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
What is the current price of MYOV stock?
The current stock price of MYOV is 26.98 USD. The price decreased by -0.04% in the last trading session.
What is the dividend status of Myovant Sciences Ltd?
MYOV does not pay a dividend.
How is the ChartMill rating for Myovant Sciences Ltd?
MYOV has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does Myovant Sciences Ltd belong to?
Myovant Sciences Ltd (MYOV) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for MYOV stock?
The Revenue of Myovant Sciences Ltd (MYOV) is expected to grow by 81.1% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for Myovant Sciences Ltd?
Myovant Sciences Ltd (MYOV) will report earnings on 2023-05-08, after the market close.